ABVC vs. DRRX, LEXX, ACXP, XLO, EYEN, VYNE, FBIO, MRKR, LPCN, and CARA
Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include DURECT (DRRX), Lexaria Bioscience (LEXX), Acurx Pharmaceuticals (ACXP), Xilio Therapeutics (XLO), Eyenovia (EYEN), VYNE Therapeutics (VYNE), Fortress Biotech (FBIO), Marker Therapeutics (MRKR), Lipocine (LPCN), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
ABVC BioPharma has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
DURECT presently has a consensus target price of $27.50, suggesting a potential upside of 2,100.00%. Given ABVC BioPharma's higher probable upside, analysts plainly believe DURECT is more favorable than ABVC BioPharma.
In the previous week, DURECT had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for DURECT and 4 mentions for ABVC BioPharma. DURECT's average media sentiment score of 1.38 beat ABVC BioPharma's score of 0.32 indicating that ABVC BioPharma is being referred to more favorably in the news media.
DURECT has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
DURECT received 316 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 11.9% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
DURECT has a net margin of -279.77% compared to DURECT's net margin of -50,504.00%. DURECT's return on equity of -207.72% beat ABVC BioPharma's return on equity.
Summary
DURECT beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.
Get ABVC BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABVC BioPharma Competitors List
Related Companies and Tools
